Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Quakkelaar, Esther D ^a   Redeker, Anke ^a   Haddad, Elias K ^b,l   Harari, Alexandre ^c,d   McCaughey, Stella Mayo ^e   Duhen, Thomas ^f   Filali Mouhim, Abdelali ^b   Goulet, Jean Philippe ^b   Loof, Nikki M ^a   Ossendorp, Ferry ^a   Perdiguero, Beatriz ^g   Heinen, Paul ^g   Gomez, Carmen E ^g   Kibler, Karen V ^h   Koelle, David M ^e,k   Sékaly, Rafick P ^b   Sallusto, Federica ^f   Lanzavecchia, Antonio ^f   Pantaleo, Giuseppe ^c,d   Esteban, Mariano ^g   Tartaglia, Jim ⁱ   Jacobs, Bertram L ^h   Melief, Cornelis J M ^a,j   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d Swiss Vaccine Research Institute   (Switzerland)

^e UNIVERSITY OF WASHINGTON   (United States)

^f INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^g CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^h ARIZONA STATE UNIVERSITY   (United States)

ⁱ SANOFI PASTEUR   (France)

^j ISA Pharmaceuticals BV   (Netherlands)

^k Fred Hutchinson Cancer Research Center   (United States)

^l Vaccine and Gene Therapy Institute of Florida   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD86 ANTIGEN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON; LIVE VACCINE; NEF PROTEIN; POL PROTEIN; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DNA MODIFICATION; DRUG SCREENING; GENE DELETION; GENE EXPRESSION REGULATION; HOST RANGE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; NYVAC C; NYVAC C DELTA B19R; NYVAC C KC; NYVAC C KC DELTA B19R; PERIPHERAL BLOOD MONONUCLEAR CELL; POXVIRUS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; VACCINE PRODUCTION; VIRUS MUTANT; VIRUS REPLICATION; ANIMAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; CELL PROLIFERATION; CROSS REACTION; CYTOLOGY; GENE EXPRESSION; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HAMSTER; HELA CELL; IMMUNIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; POXVIRIDAE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD86; CELL PROLIFERATION; CRICETINAE; CROSS REACTIONS; DENDRITIC CELLS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; GENETIC VECTORS; HELA CELLS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; INTERFERON-ALPHA; POXVIRIDAE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRAL PROTEINS;

EID: 79951911508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016819     Document Type: Article

References (61)

1. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
2. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
3. Sekaly RP, (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
5. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655.
6. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, et al. (1999) Emergence of CTL Coincides with Clearance of Virus During Primary Simian Immunodeficiency Virus Infection in Rhesus Monkeys. J Immunol 162: 5127-5133.
7. Carrington M, O'Brien SJ, (2003) The Influence of HLA Genotype on AIDS. Annu Rev Med 54: 535-551.
8. Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, et al. (2005) HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load. J Virol 79: 10218-10225.
9. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7: 173-178.
10. McNeil AJ, Yap PL, Gore SM, Brettle RP, McColl M, et al. (1996) Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM 89: 177-186.
11. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97: 2709-2714.
12. O'Connor DH, Mothe BR, Weinfurter JT, Fuenger S, Rehrauer WM, et al. (2003) Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte Responses. J Virol 77: 9029-9040.
13. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, et al. (2006) Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239. J Virol 80: 5875-5885.
14. Tartaglia J, Cox WI, Pincus S, Paoletti E, (1994) Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand 82: 125-129.
15. Gomez CE, Najera JL, Krupa M, Esteban M, (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97-120.
16. Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, et al. (2008) EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26: 3153-3161.
17. Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, et al. (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25: 1969-1992.
18. Gomez CE, Najera JL, Jimenez EP, Jimenez V, Wagner R, et al. (2007) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25: 2863-2885.
19. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, et al. (2008) An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77.
20. McCormack S, Stohr W, Barber T, Bart PA, Harari A, et al. (2008) EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26: 3162-3174.
21. Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, et al. (2009) Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. J Virol 83: 5881-5889.
22. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, et al. (1992) NYVAC: a highly attenuated strain of vaccinia virus. Virology 188: 217-232.
23. Perkus ME, Tartaglia J, Paoletti E, (1995) Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 58: 1-13.
24. Paoletti E, (1996) Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 93: 11349-11353.
25. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, et al. (2008) Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 82: 2975-2988.
26. Hel Z, Nacsa J, Tsai WP, Thornton A, Giuliani L, et al. (2002) Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques. Virology 304: 125-134.
27. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, et al. (1998) Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177: 1664-1673.
28. Esteban M, (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5: 867-871.
29. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, et al. (2002) Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 169: 4778-4787.
30. Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, et al. (2002) Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 169: 5347-5357.
31. Najera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M, (2010) Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5: e11406.
32. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
33. Symons JA, Alcami A, Smith GL, (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81: 551-560.
34. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM, (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270: 15974-15978.
35. Alcami A, Symons JA, Smith GL, (2000) The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74: 11230-11239.
36. Perdiguero B, Esteban M, (2009) The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29: 581-598.
37. Alcami A, Smith GL, (1995) Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69: 4633-4639.
38. Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM, Esteban M, (2006) Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 80: 6033-6047.
39. Oguiura N, Spehner D, Drillien R, (1993) Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J Gen Virol 74: 1409-1413.
40. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Limbach K, et al. (1990) Vaccinia virus host range genes. Virology 179: 276-286.
41. Sutter G, Ramsey-Ewing A, Rosales R, Moss B, (1994) Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol 68: 4109-4116.
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550.
43. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, et al. (2008) A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29: 150-164.
44. Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, et al. (2007) Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 81: 8707-8721.
45. Espmark JA, hlqvist-Roth L, Sarne L, Persson A, (1978) Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique. Tissue Antigens 11: 279-286.
46. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, et al. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602.
47. Shen X, Wong SBJ, Buck CB, Zhang J, Siliciano RF, (2002) Direct Priming and Cross-Priming Contribute Differentially to the Induction of CD8+ CTL Following Exposure to Vaccinia Virus Via Different Routes. J Immunol 169: 4222-4229.
48. Sigal LJ, Crotty S, Andino R, Rock KL, (1999) Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398: 77-80.
49. Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, et al. (2005) Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. J Virol 79: 6554-6559.
50. Melief CJM, (2008) Cancer Immunotherapy by Dendritic Cells. Immunity 29: 372-383.
51. van Montfoort N, Camps MG, Khan S, Filippov DV, Weterings JJ, et al. (2009) Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A 106: 6730-6735.
52. Bins AD, Wolkers MC, van dB, Haanen JB, Schumacher TN, (2007) In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 179: 2126-2133.
53. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, et al. (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83-93.
54. Jing L, Chong TM, McClurkan CL, Huang J, Story BT, et al. (2005) Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol 175: 7550-7559.
55. Terajima M, Orphin L, Leporati AM, Pazoles P, Cruz J, et al. (2008) Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol 69: 815-825.
56. Jing L, McCaughey SM, Davies DH, Chong TM, Felgner PL, et al. (2009) ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods 347: 36-45.
57. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, et al. (2007) Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A 104: 16233-16238.
58. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
59. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, et al. (1990) Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 87: 1663-1667.
60. Smith GK, (2005) Limma: linear models for microarray data. In: R.Gentleman, V.Carey, S.Duboit, R.Irizarry, W.Huber, editors. Bioinformatics and computational biology solutions using R and Bioconductor New York Springer pp. 397-420.
61. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 85: 289-300.